| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 2,506,400 | 1,995,800 | 3,090,200 | 2,011,800 |
| Marketable securities | 5,937,200 | 5,473,800 | 5,259,200 | 7,784,700 |
| Accounts receivable, net | 5,687,100 | 5,610,000 | 5,561,000 | 6,107,100 |
| Inventories | 3,254,400 | 3,205,600 | 3,192,400 | 3,018,000 |
| Prepaid expenses and other current assets | 595,600 | 574,300 | 468,900 | 412,000 |
| Total current assets | 17,980,700 | 16,859,500 | 17,571,700 | 19,333,600 |
| Marketable securities | 10,285,700 | 10,058,200 | 9,276,300 | 8,490,900 |
| Property, plant, and equipment, net | 5,002,300 | 4,840,700 | 4,694,200 | 4,439,200 |
| Intangible assets, net | 1,380,900 | 1,351,700 | 1,167,000 | 1,120,100 |
| Deferred tax assets | 3,846,700 | 3,572,200 | 3,442,900 | 3,015,100 |
| Other noncurrent assets | 1,673,100 | 1,536,900 | 1,393,100 | 1,043,000 |
| Total assets | 40,169,400 | 38,219,200 | 37,545,200 | 37,441,900 |
| Accounts payable | 903,800 | 723,900 | 705,500 | 497,300 |
| Accrued expenses and other current liabilities | 2,975,700 | 2,461,200 | 2,241,800 | 2,536,500 |
| Deferred revenue | 545,600 | 481,900 | 619,300 | 627,200 |
| Total current liabilities | 4,425,100 | 3,667,000 | 3,566,600 | 3,661,000 |
| Long-term debt | 1,985,500 | 1,985,100 | 1,984,800 | 1,984,000 |
| Finance lease liabilities | 720,000 | 720,000 | 720,000 | 720,000 |
| Deferred revenue | 219,200 | 206,300 | 211,800 | 207,400 |
| Other noncurrent liabilities | 1,861,800 | 1,701,900 | 1,674,400 | 1,543,600 |
| Total liabilities | 9,211,600 | 8,280,300 | 8,157,600 | 8,116,000 |
| Common stock-Common Class A | 0 | 0 | 0 | 0 |
| Common stock-Common Stock | 100 | 100 | 100 | 100 |
| Additional paid-in capital | 13,787,300 | 13,490,800 | 13,192,100 | 12,702,800 |
| Retained earnings | 35,045,800 | 33,680,200 | 32,384,400 | 30,755,200 |
| Accumulated other comprehensive income (loss) | 69,000 | 52,500 | 29,100 | 60,200 |
| Treasury stock, at cost 32.7 shares in 2025 and 28.2 shares in 2024 | 17,944,400 | 17,284,700 | 16,218,100 | 14,192,400 |
| Total stockholders' equity | 30,957,800 | 29,938,900 | 29,387,600 | 29,325,900 |
| Total liabilities and stockholders' equity | 40,169,400 | 38,219,200 | 37,545,200 | 37,441,900 |
REGENERON PHARMACEUTICALS, INC. (REGN)
REGENERON PHARMACEUTICALS, INC. (REGN)